<DOC>
	<DOCNO>NCT02287831</DOCNO>
	<brief_summary>The purpose study assess safety efficacy umbilical cord mesenchymal stem cell diabetes peripheral arterial disease .</brief_summary>
	<brief_title>Umbilical Cord Mesenchymal Stem Cells Injection Diabetes Secondary Peripheral Arterial Disease</brief_title>
	<detailed_description>Diabetes common chronic disease significant morbidity mortality . One devastate complication diabetes peripheral arterial disease ( PAD ) , may result limb loss.In study , patient divide 3 dose treatment group ( 6.29 × 107,9.43 × 107 14.15 × 107 cells/m2 ) 。After 4 8 week , patient inject number cell . Follow-up index include : efficacy ( pain , cold , numbness , Intermittent claudication distance , skin temperature，limb cyanosis area， area depth ulcer , gangrene range，ankle-brachial index , Transcutaneous partial pressure oxygen , low limb amputation rate , blood perfusion , Digital subtraction angiography ) safety ( infection injection site , tumour generation ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Age 1875 year 2 . Patients confirm diagnosed diabetes secondary peripheral vascular disease , anklebrachial index &lt; 0.9 3 . Poor distal arterial outflow tract 4 . Patient least 3 month conservative treatment , result little improvement 5 . Poor physical condition tolerate surgery 6 . Patients willing participate study sign inform consent . 1 . Renal function damage ( 2 X upper normal range ) Liver function damage ( 3 X upper normal range ) 2 . Severe acute organ damage 3 . Presence malignancy 4 . Pregnancy lactate patient 5 . HIV positive 6 . ABI≧0.9 7 . A history severe allergy relate cell therapy 8 . Conservative treatment &lt; 3 month 9 . Acute limb ischemia 10 . Local obvious infection uncontrolled 11 . Alcoholics drug abuser within year 12 . Severe psychiatric disorder . 13 . Patients need surgical treatment 14 . Above ankle gangrene 15 . Patients factor consider suitable participate study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>